Lantheus Medical Imaging

Quote
anonymous said:
This was just posted September 1st, 2015.....

Lantheus (NASDAQ:LNTH) had a labeling revision for Definity, an ultrasound contrast agent indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border. It comes with warning of rare occurrences of cardiopulmonary reactions. Definity had revenue of $278 million in the quarter ending June 2015, up 21% from the same quarter last year.
Click to expand...

"rare occurrences of cardiopulmonary reactions" means there have been enough so that FDA required the labeling warning. $278 million in sales for the quarter is a good number. Remains to be seen if it is repeatable quarter after quarter, or if they just flooded the market with product ahead of the IPO stock offering for window dressing.
 






anonymous said:
"rare occurrences of cardiopulmonary reactions" means there have been enough so that FDA required the labeling warning. $278 million in sales for the quarter is a good number. Remains to be seen if it is repeatable quarter after quarter, or if they just flooded the market with product ahead of the IPO stock offering for window dressing.
Click to expand...
OOOHH, I think that with new leadership, the phoenix is about to rise higher and higher!
 






anonymous said:
"rare occurrences of cardiopulmonary reactions" means there have been enough so that FDA required the labeling warning. $278 million in sales for the quarter is a good number. Remains to be seen if it is repeatable quarter after quarter, or if they just flooded the market with product ahead of the IPO stock offering for window dressing.
Click to expand...

Check those numbers. That would represent 1000% market growth. Don't believe all that is posted.
 






anonymous said:
This was just posted September 1st, 2015.....

Lantheus (NASDAQ:LNTH) had a labeling revision for Definity, an ultrasound contrast agent indicated for use in patients with suboptimal echocardiograms to opacify the left ventricular chamber and to improve the delineation of the left ventricular endocardial border. It comes with warning of rare occurrences of cardiopulmonary reactions. Definity had revenue of $278 million in the quarter ending June 2015, up 21% from the same quarter last year.
Click to expand...

Definity revenue of $278 million in the quarter ending June 2015 is total BS. "Worldwide LMI revenue (all products) for the second quarter of 2015 totaled $73.3 million, representing a decrease of 3% as-reported over $75.6 million reported for the second quarter of 2014. The Company anticipates (hopes!!) worldwide revenue for full-year 2015 of approximately $293 million to $297 million".

Looks like the phoenix just got shot down again!
 






anonymous said:
Definity revenue of $278 million in the quarter ending June 2015 is total BS. "Worldwide LMI revenue (all products) for the second quarter of 2015 totaled $73.3 million, representing a decrease of 3% as-reported over $75.6 million reported for the second quarter of 2014. The Company anticipates (hopes!!) worldwide revenue for full-year 2015 of approximately $293 million to $297 million".

Looks like the phoenix just got shot down again!
Click to expand...

During the company's heydays, Cardiolite alone was bringing in over 2X more a year than LMI hopes to take in from all its products in 2015. Just goes to show how far the company fallen and how insignificant of a force it has become. This is what happens when venture capitalists get hold of a company with the objective of draining every penny out of it any way they can. More of the same is sure to follow.
 
























anonymous said:
Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) ended Monday session in red amid volatile trading. The shares closed down 0.77 points or 13.39% at $4.98 ... OINK OINK
Click to expand...

Ten times the typical trading volume during the price dive means a big investor bailed out. Since then the price has gone down further. Now hovering around 4. Expect some pain to be felt by the troops if the price stays down...just in time for the Holidays.
 






anonymous said:
During the company's heydays, Cardiolite alone was bringing in over 2X more a year than LMI hopes to take in from all its products in 2015. Just goes to show how far the company fallen and how insignificant of a force it has become. This is what happens when venture capitalists get hold of a company with the objective of draining every penny out of it any way they can. More of the same is sure to follow.
Click to expand...


Or this is what happens when you have a product like Cardiolite go off patent
 






anonymous said:
Or this is what happens when you have a product like Cardiolite go off patent
Click to expand...

Competent owners and management recognize the ramifications of a product going off patent. The answer is called a "pipeline". Like the pretty much non existent one at LMI. The greedy owners have no intent of wasting "their"money looking to create future products. What they have chosen to do is continue meager bankrolling of the PET agent that was developed and brought along by their predecessors. Since the LMI team could screw up boiling water, there's a good chance they'll mess this up too or run out of available funds to get it to the goal line. Look for them to sell it off for some fast cash to pay the bills so they can continue to drain what they can in profits from a flailing company.
 




























































Top Bottom
Back
Quote